Both raloxifene and fulvestrant target estrogen receptors, though through different mechanisms: raloxifene selectively modulates receptor activity, activating estrogenic pathways in some tissues while blocking them in others (National Institute of Diabetes Digestive Kidney Diseases, 2012), whereas fulvestrant creates pure antiestrogenic effects by inhibiting receptor dimerization and enhancing receptor degradation (Carlson, 2005). This evidence concerns the gene ESR1 and glycogen storage disease VI.